A RANDOMIZED TRIAL OF CYCLOPHOSPHAMIDE WITH AND WITHOUT LOW-DOSE ALPHA-INTERFERON IN THE TREATMENT OF NEWLY DIAGNOSED MYELOMA

被引：7

作者：

AITCHISON, R ^{[1
]}

WILLIAMS, A ^{[1
]}

SCHEY, S ^{[1
]}

NEWLAND, AC ^{[1
]}

机构：

[1] ROYAL LONDON HOSP,DEPT HAEMATOL,LONDON E1 1BB,ENGLAND

来源：

LEUKEMIA & LYMPHOMA | 1993年 / 9卷 / 03期

关键词：

ALPHA-INTERFERON; CHEMOTHERAPY; MYELOMA;

D O I：

10.3109/10428199309147377

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The role of alpha-interferon (IFN) in initial treatment of multiple myeloma is controversial. We have conducted a trial of cyclophosphamide with and without low dose IFN in newly diagnosed myeloma. Thirty four patients, mean age 63 were all given cyclophosphamide 600mg/m2 IV every 21 days while 17 were randomised to also receive IFN at a dose equivalent to 6mU per week. In the IFN group 8/15 assessable patients (53%) had a greater than 50% reduction in paraprotein compared with 4/16 (25%) of controls (p < 0.05). However the median duration of response was the same in the two groups (IFN 8 months, controls 8.5 months). After a median follow up of 28 months there is no significant difference in survival. Toxicity including myelosuppression was commoner in the IFN group. These findings suggest that the addition of IFN to cyclophosphamide is not likely to offer major benefits in treating myeloma.

引用

页码：243 / 246

页数：4

共 18 条

[11]

Mandelli F., Avvisati S., Amadori S., Et al., Maintenance treatment with recombinant interferon alfa-2B in patients with multiple myeloma responding to conventional induction chemotherapy, New England Journal of Medicine, 322, 20, pp. 1430-1434, (1990)

[12]

Myelomatosis, comparison of melphalan and cyclophosphamide therapy, B.M.J., 1, pp. 640-641, (1971)

[13]

Korst D.R., Clifford G.O., Fowler W.M., Louis J., Will J., Wilson H.E., Multiple myeloma II, analysis of cyclophosphamide therapy in 165 patients, JAMA, 189, pp. 758-762, (1964)

[14]

Mellstedt H., Osterborg A., Bjorkholm M., Bjoreman M., Brennning G., Treatment of multiple myeloma with interferon alpha: the Scandinavian Experience, British Journal of Haematology, 79, pp. 21-25, (1991)

[15]

Monturoro A., De Rosa L., De Blasio A., Pacilli L., Petti N., De Laurenzi A., AIfa-2a-interferon/melphalan/-prednisone versus melphalan/prednisone in previously untreated patients with multiple myeloma, British Journal of Haematology, 76, pp. 365-368, (1990)

[16]

MacLennan I.A.C., Chapman C., Dunn J., Kelly K., Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis, Lancet, 339, pp. 200-205, (1992)

[17]

Ludwig H., Cohen A.M., Huber H., Nachbaur D., Et al., Interferon Alfa-2b with VMCP compared to VMCP alone for induction and Interferon Alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results, Eur. J. Cancer, 27, pp. S40-S45, (1991)

[18]

Case D.C., Sonneborn H.L., Paul S.D., Et al., Phase II study of rDNA alpha-2 interferon (Intron A) in multiple myeloma utilizing an escalating induction phase, Cancer Treat. Rep., 70, (1986)

← 1 2 →